Arcus Biosciences’ cancer drug gets orphan drug status

8 hours ago 1
World Cancer Day banner design with colorful ribbons for different types of cancer on a background and copy space in 3D illustration

Adrian Vidal/iStock via Getty Images

Arcus Biosciences (NYSE:RCUS) said on Thursday that its experimental drug candidate, quemliclustat, has received orphan drug status from the U.S. FDA.

Quemliclustat is a type of medication that works by blocking a specific protein involved in cancer growth. This drug is

Recommended For You

More Trending News

Read Entire Article